Gilead Sciences, Inc. Revenue 2007–2025
Gilead Sciences, Inc. reported $29.44B of revenue for fiscal 2025. That was 2.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +19.3%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $29.44B | +2.4% |
| FY 2024 | $28.75B | +6.0% |
| FY 2023 | $27.12B | -0.6% |
| FY 2022 | $27.28B | -0.1% |
| FY 2021 | $27.30B | +10.6% |
| FY 2020 | $24.69B | +10.0% |
| FY 2019 | $22.45B | +1.5% |
| FY 2018 | $22.13B | -15.2% |
| FY 2017 | $26.11B | -14.1% |
| FY 2016 | $30.39B | -6.9% |
| FY 2015 | $32.64B | +31.1% |
| FY 2014 | $24.89B | +122.2% |
| FY 2013 | $11.20B | +15.5% |
| FY 2012 | $9.70B | +15.7% |
| FY 2011 | $8.39B | +5.5% |
| FY 2010 | $7.95B | +13.4% |
| FY 2009 | $7.01B | +31.4% |
| FY 2008 | $5.34B | +26.1% |
| FY 2007 | $4.23B | — |
Source: Gilead Sciences, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open GILD 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Gilead Sciences, Inc. reported $29.44B of revenue for fiscal 2025. That was 2.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +19.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Gilead Sciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeGilead Sciences, Inc. — frequently asked questions
What is Gilead Sciences, Inc.'s revenue?
Gilead Sciences, Inc. (GILD) reported revenue of $29.44B for fiscal year 2025, per its SEC filings.
How has Gilead Sciences, Inc.'s revenue changed over time?
Between fiscal 2007 and 2025, GILD's revenue grew at roughly 11.4% per year (compound annual rate), from $4.23B to $29.44B.
Where does this data come from?
Figures are computed from Gilead Sciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.